Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

It is a similar approach to that of another form of oncology treatment that is ... The financing saw Merck, Bristol Myers Squibb, and Novartis all choose to invest in the biotech.

It’s clear the growth rate for oncology products is slowing. Figure 1 Global Oncology Sales and Growth Considering this moderating growth, IMS conducted an Oncology Launch Excellence Study to ...